BERLIN (Reuters) – Switzerland has agreed to buy just over 1,200 doses of AstraZeneca’s tixagevimab/cilgavimab, a combination drug designed to both prevent and treat COVID-19, the government said in a statement on Wednesday.
The drug, originally only for preventive use, has also been found to be effective in treating people who already have COVID-19, the statement said citing recent studies.
This is Switzerland’s second contract with the British pharmaceutical company to reserve the product, which has not yet received authorisation but may be used to treat patients while the authorisation procedure is ongoing, the government added.
(Writing by Rachel More)
